

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-5 (canceled)

6.(new) Alkaloid K252 or of their physiologically equivalent derivatives selected from esters, amides, salts, N-alkylated or N-acylated derivatives or derivatives obtained by chemical synthesis aimed to reduce the systemic absorption of the product by means of spacers associated to proteins or other physiologically inactive large molecules.

7.(new) The alkaloid K252 as claimed in claim 6, wherein the active ingredient is K252a or K252b.

8.(new) A topical pharmaceutical composition comprising an alkaloid K252 according to claim 6, in admixture with vehicles and/or excipients.

9.(new) The composition as claimed in claim 8 in the form of ointments, gels, lotions, powders and medicated plasters.

10.(new) The composition as claimed in claim 8 wherein the active ingredient is K252a or K252b.

11.(new) A method for treating hyperproliferation of keratinocytes, comprising administering an effective amount of pharmaceutical composition according to claim 8 to a subject in need thereof.

12.(new) The method according to claim 11, further comprising administering to said subject of PUVA treatment or photodynamic treatment.

13.(new) The method according to claim 11, wherein said subject has psoriasis and/or a skin tumour.

14.(new) A method for preparing a pharmaceutical composition comprising adding an alkaloid K252 compound according to claim 6 with a pharmaceutical vehicle and/or excipient.